**In the claims:**

1. (currently amended). An isolated polypeptide, said polypeptide comprising a material selected from the group consisting of: a) an amino acid sequence set out in SEQ ID NO: 1; ~~b) a derivative of an amino acid sequence set out in SEQ ID NO: 1, wherein said derivative is an amino acid sequence set out in SEQ ID NO: 1 having one or more amino acid substitutions, deletions or insertions;~~ and b) ~~c)~~ a fragment of SEQ ID NO: 1 ~~an amino acid sequence of a) or b)~~, said fragment comprising SEQ ID NO: 3 or SEQ ID NO: 10 ~~at least ten amino acids~~.

2. (canceled).

3. (original). The isolated polypeptide of claim 1, wherein said isolated polypeptide is operably linked to a second amino acid sequence to generate a fusion polypeptide.

4. (withdrawn): An isolated or recombinant nucleic acid molecule, said isolated or recombinant nucleic acid molecule comprising: a) a nucleic acid sequence set out in SEQ ID NO:2 or an RNA transcribed therefrom; b) a nucleic acid sequence encoding a derivative of an amino acid sequence set out in SEQ ID NO: 1, wherein said derivative comprises an amino acid sequence set out in SEQ ID NO: 1 having one or more substitutions, deletions or insertions; c) a nucleic acid sequence encoding a fragment of a amino acid sequence set out in SEQ ID NO:1; d) a nucleic acid sequence complementary to a nucleic acid sequence of a) or b); e) a nucleic acid sequence encoding a polypeptide, wherein said polypeptide is identical to an amino acid sequence of a), b) or c); or f) a nucleic acid sequence having substantial identity to a nucleic acid sequence of a), b), c) and d).

5. (withdrawn): A vector comprising at least one nucleic acid molecule of claim 4.

6. (withdrawn): A host cell comprising the vector of claim 5.

7. (withdrawn): A method for screening and/or diagnosing breast cancer or monitoring and/or assessing breast cancer treatment in a subject, said method comprising detecting and/or quantifying an amount of a polypeptide of claim 1 or a nucleic acid molecule of claim 4 in a biological sample of said subject.

8. (withdrawn): An antibody capable of binding specifically to a polypeptide of claim 1.

9. (withdrawn): The antibody of claim 8, wherein the antibody is a monoclonal antibody, a bispecific antibody, a chimeric antibody, or a humanised antibody.

10. (withdrawn): The antibody of claim 9, wherein the antibody is conjugated to a therapeutic moiety, said therapeutic moiety selected from the group consisting of a second antibody or a fragment or derivative thereof, a cytotoxic agent and a cytokine.

11. (withdrawn): A method of screening for agents capable of interacting with at least one polypeptide of claim 1, said method comprising: (a) contacting a polypeptide of claim 1 with a candidate agent; and (b) determining if the candidate agent interacts with said polypeptide, wherein determination of an interaction of a candidate agent with said polypeptide identifies a candidate agent capable of interacting with at least one polypeptide of claim 1.

12. (withdrawn): The method according to claim 11, wherein the determination of an interaction of a candidate agent with the polypeptide comprises quantitatively detecting binding of the candidate agent to said polypeptide.

13. (withdrawn): A method of screening for agents capable of modulating i) expression and/or activity of a polypeptide of claim 1, or ii) expression of a nucleic acid molecule of claim 4, said method comprising: a) comparing the expression and/or activity of said polypeptide or the expression of said nucleic acid molecule in the presence of a candidate agent with the expression and/or activity of said polypeptide or the expression of said nucleic acid molecule in the absence of the candidate agent or in the presence of a control

agent; and b) determining whether the presence of the candidate agent modulates the expression and/or activity of said polypeptide or the expression of said nucleic acid molecule.

14. (withdrawn): The method of claim 13 wherein the expression and/or activity level of said polypeptide or the expression level of said nucleic acid molecule is compared to a predetermined reference range.

15. (withdrawn): The method of claim 13 wherein step (b) further comprises selecting an agent capable of modulating the expression and/or activity of said polypeptide or the expression of said nucleic acid molecule and testing said agent for use as a therapeutic or prophylactic anti-breast cancer agent.

16. (withdrawn): An agent identified by the method of claim 13, wherein said agent alters the expression and/or activity of said polypeptide or the expression of said nucleic acid molecule.

17. (currently amended). A medicament for use in ~~prophylaxis and/or~~ treatment of cancer, said medicament comprising a material selected from the group consisting of a) at least one polypeptide of claim 1~~; b) at least one nucleic acid molecule of claim 4f); c) at least one antibody capable of binding specifically to said at least one polypeptide; and d) at least one agent capable of modulating the expression and/or activity of said at least one polypeptide or the expression of said nucleic acid molecule~~.

18. (currently amended). The medicament of claim 17, wherein said medicament is used for ~~prophylaxis and/or~~ treatment of breast cancer.

19. (currently amended). A pharmaceutical composition comprising a material selected from the group consisting of: a) at least one polypeptide of claim 1~~; b) at least one nucleic acid molecule of claim 4f); c) at least one antibody capable of binding specifically to said at least one polypeptide; d) at least one agent capable of modulating the expression and/or~~

~~activity of said at least one polypeptide or the expression of said nucleic acid molecule~~ and ~~e) one or more of the above together with~~ at least one of pharmaceutically acceptable excipients, adjuvants, carriers and diluents.

20. (withdrawn): A method for prophylaxis and/or treatment of breast cancer in a subject, said method comprising administering to said subject a therapeutically effective amount of: a) at least one polypeptide of claim 1; b) at least one nucleic acid molecule of claim 4f); d) at least one antibody capable of binding specifically to said at least one polypeptide; and e) at least one agent capable of modulating the expression and/or activity of said at least one polypeptide or the expression of said nucleic acid molecule.

21. (original). The pharmaceutical composition of claim 19 wherein the pharmaceutical composition is a vaccine.

22. (new). The isolated polypeptide of claim 1, wherein said fragment of SEQ ID NO: 1 consists of SEQ ID NO: 3 or SEQ ID NO: 10.